EUVIMEDEUVIMED entdecken
Crossref

Relación costo-beneficio entre el Emicizumab y el concentrado de factor de la coagulación VIII para el manejo profiláctico de la hemofilia A en pacientes pediátricos

Valeria Pérez Martínez, Ingrid Pérez Robledo, Karla Dzul Rosado, Gaspar Peniche Lara

Ciencia y Humanismo en la Salud · 2025

DOI: 10.32776/wa8b0967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ciencia y Humanismo en la Salud, 2025. Verfasst von Valeria Pérez Martínez und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To analyze the cost-benefit relationship between emicizumab and coagulation factor VIII concentrate in the prophylactic management of hemophilia A in pediatric patients. Material and methods: descriptive observational study with a non-experimental cross-sectional design, scientific research articles from the Pubmed and Scielo search engines were analyzed, among others published from 2019 to date. Cost analysis was performed using Excel software.

Results

The cost of prophylactic treatment with emicizumab is higher than the cost compared to treatment with FVIII if the therapeutic scheme is estimated in one year, however improvements are obtained in the quality of life of the patient and the number of bleedings decreases. Other complications with the use of emicizumab. Conclusions:It is 86% higher than the cost of factor VIII, however, the former decreases the risk of bleeding and other complications, reducing the total cost of therapy by avoiding hospitalizations, transfers, diagnoses, among others, in addition to increasing quality of patient life.

Zitieren

APA

Martínez, V. P., Robledo, I. P., Rosado, K. D., & Lara, G. P. (2025). Relación costo-beneficio entre el Emicizumab y el concentrado de factor de la coagulación VIII para el manejo profiláctico de la hemofilia A en pacientes pediátricos. Ciencia y Humanismo en la Salud. https://doi.org/10.32776/wa8b0967

Vancouver

Martínez VP, Robledo IP, Rosado KD, Lara GP. Relación costo-beneficio entre el Emicizumab y el concentrado de factor de la coagulación VIII para el manejo profiláctico de la hemofilia A en pacientes pediátricos. Ciencia y Humanismo en la Salud. 2025. doi:10.32776/wa8b0967

BibTeX
@article{Martnez2025,
  author = {Martínez, Valeria Pérez and Robledo, Ingrid Pérez and Rosado, Karla Dzul and Lara, Gaspar Peniche},
  title = {Relación costo-beneficio entre el Emicizumab y el concentrado de factor de la coagulación VIII para el manejo profiláctico de la hemofilia A en pacientes pediátricos},
  journal = {Ciencia y Humanismo en la Salud},
  year = {2025},
  doi = {10.32776/wa8b0967}
}
Kostenlos starten →